2006
DOI: 10.2214/ajr.05.0437
|View full text |Cite
|
Sign up to set email alerts
|

18F-Choline PET/CT for Initial Staging of Advanced Prostate Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
6
0
5

Year Published

2007
2007
2015
2015

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 20 publications
(12 citation statements)
references
References 7 publications
1
6
0
5
Order By: Relevance
“…However, the short half-life of 11 C-choline is the main cause of practical restriction. 18 F-choline has a longer half-life than 11 C-choline and has been used to diagnose prostate carcinoma [24,25]. The sensitivity values may be affected by differences in urinary secretion, because there is no other reason why these differences between 18 F-choline and 11 C-choline should lead to improved accuracy of PET/CT.…”
Section: Discussionmentioning
confidence: 99%
“…However, the short half-life of 11 C-choline is the main cause of practical restriction. 18 F-choline has a longer half-life than 11 C-choline and has been used to diagnose prostate carcinoma [24,25]. The sensitivity values may be affected by differences in urinary secretion, because there is no other reason why these differences between 18 F-choline and 11 C-choline should lead to improved accuracy of PET/CT.…”
Section: Discussionmentioning
confidence: 99%
“…Il a été ensuite montré que les réci-dives pouvaient être décelées grâce à la TEP/TDM à la FCH, même quand la concentration plasmatique de PSA était < 5 ng/mL [52] : dans ces conditions, un résultat vrai positif a été obtenu chez 41 % des 17 patients. Notre expérience, acquise dans le cadre d'un protocole de recherche clinique multicentrique, nous a permis de rapporter des cas où ce radiopharmaceutique avait permis de résoudre des problèmes diagnostiques [49,53] (figures 6 à 8). L'équipe d'Aviano a récemment précisé, grâce à l'étude de 100 patients, la force et les limitations de la TEP/TDM à la FCH dans cette indication [54].…”
Section: Récidive Biologiqueunclassified
“…За по-следнее десятилетие ПЭТ и гибридные технологии ПЭТ/КТ, ПЭТ/МРТ заняли важное место в диагности-ке и оценке эффективности лечения злокачественных опухолей. При РПЖ растущий интерес вызывают ра-диофармпрепараты (РФП) на основе холина, мечен-ные 11 С или 18 F. Биологической основой для повышен-ного накопления меченого холина клетками РПЖ является избыточная экспрессия в них холинкиназы даже по сравнению с другими опухолями [25][26][27][28][29][30][31][32][33].…”
Section: Introductionunclassified